Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record.

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

Bahjat, Frances Rena, Pine, Polly R., Reitsma, Andrea, Cassafer, Gail, Baluom, Muhammad, Grillo, Sunny, Chang, Betty, Zhao, Fei Fei, Payan, Donald G., Grossbard, Elliott B., Daikh, David I. · 2008 · Arthritis & Rheumatism

Abstract

Objective: To assess whether R788, an orally bioavailable small molecule inhibitor of spleen tyrosine kinase (Syk)–dependent signaling, could modulate disease in lupus‐prone (NZB × NZW)F 1 (NZB/NZW) mice via inhibition of Fc receptor (FcR) and B cell receptor signaling. Methods: R788 was administered to NZB/NZW mice before and after disease onset. Proteinuria, blood urea nitrogen levels, and autoantibody titers were examined periodically, and overall survival and renal pathologic features were assessed following long‐term treatment (24–34 weeks). The distribution and immunophenotype of various splenic T cell and B cell subpopulations were evaluated at the time of study termination. Arthus responses in NZB/NZW mice pretreated with R788 or Fc‐blocking antibody (anti‐CD16/32) were also examined. Results: When R788 was administered prior to or after disease onset, it delayed the onset of proteinuria and azotemia, reduced renal pathology and kidney infiltrates, and significantly prolonged survival of lupus‐prone NZB/NZW mice; autoantibody titers were minimally affected throughout the study. Dose‐dependent reductions in the numbers of CD4+ activated T cells expressing high levels of CD44 or CD69 were apparent in spleens from R788‐treated mice. Minimal effects on the numbers of naive T cells expressing CD62 ligand and total CD8+ T cells per spleen were observed following long‐term drug treatment. R788 pretreatment resulted in reduced Arthus responses in NZB/NZW mice, similar to results obtained in mice pretreated with FcR‐blocking antibody. Conclusion: We demonstrate that a novel Syk‐selective inhibitor prevents the development of renal disease and treats established murine lupus nephritis. These data suggest that Syk inhibitors may be of therapeutic benefit in human lupus and related disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.23428

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 171

Metadata

Authors
Bahjat, F. R., Pine, P. R., Reitsma, A., Cassafer, G., Baluom, M., Grillo, S., Chang, B., Zhao, F. F., Payan, D. G., Grossbard, E. B., & Daikh, D. I.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-04-25
Volume
58
Issue
5
Pages
1433-1444
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2045549010
Cited by
171
References
0
FWCI
10.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. https://app.cochat.ai/papers/10.1002/art.23428
The paper
Bahjat, F. R., Pine, P. R., Reitsma, A., Cassafer, G., Baluom, M., Grillo, S., Chang, B., Zhao, F. F., Payan, D. G., Grossbard, E. B., & Daikh, D. I. (2008). An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis & Rheumatism. https://doi.org/10.1002/art.23428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.